TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis~Exclusion Criteria:~* previous H pylori-eradication therapy~* ingestion of antibiotics or bismuth within the prior 4 weeks~* patients with allergic history to the medications used~* patients with previous gastric surgery~* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- pantoprazole+bismuth+tetra+metro (Type: EXPERIMENTAL): pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
- (panto+amox+clar+metr)+(panto+amox) (Type: ACTIVE_COMPARATOR): a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 American College of Rheumatology classification criteria.~* Subjects must have active RA disease as defined by:~  * At least 6 tender joints and 6 swollen joints~ * ESR of 28 mm/hour or CRP of 2.0 mg/dL~* Subjects who have failed to respond or have been resistant to at least one DMARD (including MTX)~* Subjects in whom MTX cannot be administered for any of the reasons(incomplete response/safety concerns)~Exclusion Criteria:~* Patients who have a diagnosis of any other inflammatory arthritis~* Patients who have a secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)~* Patients who currently have, or who have a history of, a demyelinating or convulsive disease of the central nervous system (eg, multiple sclerosis, epilepsy)~* Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure~* Patients who currently have, or who have a history of, tuberculosis~* Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)~* Patients who currently have, or who have a history of, malignancy~* Female patients who are breastfeeding or pregnant, who are of childbearing potential~* Patients who previously received treatment with 2 or more anti-TNFα drugs or who previously failed to respond to treatment with 1 or more aint-TNFα drugs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- CDP870 200mg (Type: EXPERIMENTAL): 400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of CDP870

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Isotonic and Hypotonic Intravenous Maintenance Fluids In Term Newborns: Neofluid Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria are:~* Term newborns (\>37 + 0/7 weeks) aged 24 hours to 30 days with a normal baseline serum sodium level between 135-145 mmol/L,with a treatment plan to include IV fluids at \> 50% of maintenance~* Infants not received parenteral fluids in the last 24 hours before participation~* Infants receiving IV fluid administration at 50% to 100% of maintenance~Exclusion Criteria:~* Newborns with diagnoses that required specific fluid tonicity and volumes such as:~  * Severe dehydration presenting with shock~ * Syndrome of inappropriate antidiuretic hormone secretion (SIADH)~ * Renal insufficiency~ * Adrenal insufficiency~ * Diabetes mellitus and diabetes insipidus~ * Hypoxic ischemic encephalopathy~ * Major congenital anomaly~ * Patients receiving diuretic therapy~ * Patients with obvious edema~ * Heart or liver failure, portal hypertension with acid~ * Pre-post operative patients~ * Infants receiving total parenteral nutritional therapy~ * Other: all conditions that require non-standard liquid content and quantities

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: None

Study Arms:
- Isotonic fluid (Type: None): Group, received isotonic maintenance fluid containing NaCl between 131 to 154 mmol/L such as:~* Dextrose 5% in 0.9% NaCl,~* Intravenous fluid containing NaCl between 131 to 154 mmol/L
- Hypotonic fluid (Type: None): Group, received hypotonic maintenance fluid containing NaCl \< 130 mmol/L such as:~* Dextrose 5 % in 0.02 % NaCl,~* Dextrose 5% in 0.033 % NaCl~* Dextrose 5% in 0.045 % NaCl~* Intravenous fluid containing NaCl \< 130 mmol/L

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years with rheumatoid arthritis (RA)~* Seropositive participants with RA (positive for rheumatoid factor (RF) and/or anti-Citrullinated Cyclic Peptide \[CCP\])~* Active disease despite receiving one or more TNF inhibitors~* Absence of serious or active infection~Exclusion Criteria:~* Participants with serious history of heart failure (class New York Heart Association \[NYHA\] IV) or severe uncontrolled heart disease~* Participants pregnant or lactating~* Prior treatment with Mabthera®~* Participants receiving any other investigational product in the context of other clinical study~* Participants with known hypersensitivity to rituximab or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): Rituximab administered according to prescribing information and normal clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Nomegestrol Acetate/Estradiol in Random Start Rapid Endometrial Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with endometrial polyps.~Exclusion Criteria:~* Patients with other endometrial pathologies.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Patients with endometrial polyps undergone hysteroscopic polipectomy without endometrial preparation.
- Intervention (Type: EXPERIMENTAL): Patients with endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Nomegestrol Acetate/Estradiol 2.5mg/1.5mg at any time of the menstrual cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hematopoietic progenitor cell transplant subjects with chronic or Grade II-IV acute GVHD being treated with high dose immunosuppressive therapy.~* One of the following to the subject's prior immunosuppressive regimen:~  1. at least 1mg per kg per day of methylprednisolone or equivalent,~ 2. Antithymocyte globulin (ATG) for the therapy of acute GVHD,~ 3. Tacrolimus, mycophenolate mofetil, or other steroid-sparing immunosuppressive regimen.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18 to 24 years or 50 to 85 years who are available for the entire duration of the study, able to be contacted by phone, and able to complete all study procedures, including completion of an electronic diary (e-diary).~* Men and women who are able to have children, must use a reliable method of birth control for the duration of the study.~Exclusion Criteria:~* Any major illness that would substantially increase the risk associated with participation in the study, or interfere with the evaluation of the study objectives - this is determined by the local physician.~* Donation of 250 mL or more of blood within the last 3 months.~* Condition associated with prolonged bleeding time, including subjects taking anticoagulant medication or antiplatelet therapy.~* Any contraindication to vaccination or vaccine components.~* Immunocompromised persons and subjects who receive treatment with immunosuppressive therapy.~* Previous administration of S. aureus vaccination.~* Receipt of blood products or immunoglobulins within 12 months prior to study~* Participation in another trial (not including observational trials) within the last 30 days.~* Study site personnel or immediate family members (first-degree relatives).~* Women who are pregnant (as determined by urine pregnancy test) or breast-feeding.~* Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care.~* For subjects aged 65 years or older, a Mini-Mental State Examination (MMSE) score of \<=21.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): SA3Ag in both stage 1 and stage 2
- 2 (Type: EXPERIMENTAL): SA3Ag in stage 1 followed by placebo in stage 2.
- 3 (Type: PLACEBO_COMPARATOR): Placebo in both stage 1 and stage 2
- 4 (Type: EXPERIMENTAL): SA3Ag in stage 1 and no vaccine in stage 2.
- 5 (Type: PLACEBO_COMPARATOR): Placebo in stage 1 and no vaccine in stage 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with age at onset \<45 years and continuous chronic back pain for ≥ 3 months fulfills the ASAS classification criteria of axial spondyloarthritis (with the exception of the Crohn's disease)~* Subject has Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at screening and enrollment~* Subject has spinal pain score (BASDAI question #2) ≥ 4 at screening and enrollment~* Subject has had adequate therapy with non-steroidal anti-inflammatory drugs (oral NSAIDs) for back pain for at least 3 months with inadequate treatment response before enrollment~Exclusion Criteria:~* Complete ankylosis (fusion) of the spine~* Subject with active ongoing inflammatory diseases other than axSpA that might confound the evaluation of Brodalumab therapy, including reactive arthritis, spondyloarthritis associated with inflammatory bowel disease, SAPHO syndrome (pustulotic arthro-osteitis), fibromyalgia, ankylosing spinal hyperostosis, osteitis condensans ilii, spondylosis deformans, or osteoarthritis sacroiliac joint disease~* Subject has a prior history of \>1 anti-tumor necrosis factor (TNF) therapy~* Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at enrollment~* Subject has a history or evidence of a psychiatric disorder, alcohol and/or substance abuse~* Subject has severe depression based on a total score of ≥ 15 on the Patient Health Questionnaire-8 (PHQ-8) at enrollment (note: subjects with a total score of 10 to 14 on the PHQ-8 should be referred to a mental health care professional)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brodalumab (Type: EXPERIMENTAL): Brodalumab administered SC
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Blunts the Hypotensive Effect of Spinal Anesthesia in Geriatric Patients Undergoing Lower Limb Orthopedic Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 110 patients aged 60 years or older~* of the American Society of Anesthesiologists (ASA) physical status I, II or III~* undergoing lower limb orthopedic surgeries.~* A written informed consent was obtained from all patients to participate in the study.~Exclusion Criteria:~* Patients with contraindication to SA (e.g.- coagulopathy,~* thrombocytopenia,~* allergy to local anesthetic agent)~* and those on steroid or serotonin related medications (e.g. selective serotonin reuptake inhibitor) were excluded.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- D group, (n=55) (Type: ACTIVE_COMPARATOR): None
- C group, (n=55) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Texting to Improve Adherence in HIV+ With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent~* 18 years or older at the time of enrollment~* HIV-infected~* DSM-IV diagnosis Bipolar Disorder~* Taking at least one medication to treat HIV illness~* Taking at least one medication to treat bipolar disorder~* Indication of less than 100% adherence to antiretroviral (ART) medication~* Willingness to use electronic monitoring caps to track ART medication and BD medication~* Willingness to respond to text messages~Exclusion Criteria:~* Axis I psychiatric diagnosis of psychotic spectrum disorder (e.g., schizophrenia)~* Presence of a neurological condition (beyond HIV infection) known to impact cognitive functioning (e.g., Huntington's Disease, Stroke)~* Unwillingness or inability to use electronic medication monitoring technology~* Unwillingness or inability to use daily texting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Personalized Reminder Texting + Psychoeducation (iTAB) (Type: EXPERIMENTAL): Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
- Psychoeducation (CTRL) (Type: ACTIVE_COMPARATOR): Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* participants meeting Diagnostic and Statistical Manual Fifth Edition (DSM-5) criteria for BDI, BDII or BD Other Specified Bipolar (BD-OS).~* participants with mood symptoms, such as Hamilton Depression Rating Scale (Ham-D) score ≥ 15 and/or for hypomania/mild mania such as Young Mania Rating Scale (YMRS) ≥ 12.~Exclusion Criteria:~* history of significant medical illness, particularly illness associated with possible changes in cerebral tissue or cerebrovasculature (e.g. hypertension)~* history of neurologic abnormality, including significant head trauma (defined by loss of consciousness of ≥5-minutes duration), seizure disorder, cerebrovascular or neoplastic lesion, or neurodegenerative disorder.~* contraindication to MRI scanning, e.g. presence of a ferromagnetic object, including orthodontic braces, or claustrophobia.~* intelligence quotient (IQ) lower than 70~* pregnancy~* alcohol/substance use may be permitted if participant does not meet for DSM-5 current use disorder but will not be permitted for illicit substance use in the week prior to study.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 29 Years
- Healthy Volunteers: f

Study Arms:
- BE-SMART (Type: EXPERIMENTAL): Psychobehavioral intervention with focus either on teaching emotional regulation skills or regularizing daily sleep and activity levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a male or female subject 40 years of age or older~Exclusion Criteria:~* Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TD-4208-1 (Type: ACTIVE_COMPARATOR): 88 mcg
- TD-4208-2 (Type: ACTIVE_COMPARATOR): 175 mcg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Male between 19 and 39 years of age at the time of screening~2. Subjects with body mass index (BMI) between 19 and 27 at the time of screening~3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 28 days of study completion~4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements~Exclusion Criteria:~1. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) which is affect to absorption OR surgical history except appendectomy, herniotomy~2. History of allergy, cardiovascular, peripheral vascular, skin, mucous membrane, eyes, otorhinolaryngologic, respiratory, musculoskeletal, infectious disease, gastroenterologic, liver, billiary, endocrinologic, kidney, genitourinary, neuropsychiatric, hemato-oncologic problem(s) or fracture etc.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- LCB01-0371 200mg (Type: EXPERIMENTAL): LCB01-0371 IV 200 mg
- LCB01-0371 400mg (Type: EXPERIMENTAL): LCB01-0371 IV 400 mg
- LCB01-0371 800mg (Type: EXPERIMENTAL): LCB01-0371 IV 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete